Research Topics
| Jane N WinterSummaryAffiliation: Northwestern University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphomaJane N Winter
Division of Hematology Oncology and Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
Curr Opin Hematol 14:360-8. 2007..To critically assess recent advances in the treatment of indolent non-Hodgkin lymphoma with a focus on immunologically based therapies...- Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
J Clin Oncol 27:1653-9. 2009.... - Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative studyJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Blood 107:4207-13. 2006..Our finding that Bcl-6(+) cases did not benefit from the addition of R to CHOP requires independent confirmation... - Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494Jane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Clin Cancer Res 16:2435-42. 2010..S. Intergroup trial comparing conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to rituximab-CHOP (R-CHOP) induction, with or without maintenance rituximab... - Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphomaJane N Winter
Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Clin Lymphoma 5:S22-6. 2004..This review focuses on the use of 90Y ibritumomab tiuxetan combined with high-dose chemotherapy in the setting of autologous hematopoietic stem cell transplantation... - Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biologyJane N Winter
Division of Hematology Oncology, Department of Medicine and the Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Suite 850, 676 North St Clair Street, Chicago, IL 60611, USA
Curr Hematol Malig Rep 2:235-41. 2007..Studies of prognostic indicators in the context of modern therapy have the potential to identify new, rational therapeutic targets for this biologically diverse disease... - Hypoxia-inducible factor-1 {alpha} expression predicts superior survival in patients with diffuse large B-cell lymphoma treated with R-CHOPAndrew M Evens
DO, Division of Hematology Oncology, 676 N St Clair St, Suite 850, Chicago, IL 60611, USA
J Clin Oncol 28:1017-24. 2010..CONCLUSION The expression of HIF-1alpha protein is an important independent favorable prognostic factor for survival in patients with DLBCL treated with R-CHOP... - The novel expanded porphyrin, motexafin gadolinium, combined with [90Y]ibritumomab tiuxetan for relapsed/refractory non-Hodgkin's lymphoma: preclinical findings and results of a phase I trialAndrew M Evens
Lymphoma Program, Division of Hematology Oncology, The Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 North St Clair Street, Chicago, IL 60611, USA
Clin Cancer Res 15:6462-71. 2009..Motexafin gadolinium is a novel anticancer agent that targets redox-dependent pathways and enhances sensitivity of tumor cells to ionizing radiation... - A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphomaAndrew M Evens
Robert H Lurie Comprehensive Center of Northwestern University, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Br J Haematol 140:385-93. 2008..001; OS P = 0.0002). CTAP/VMAC induction followed by consolidative auto-HSCT for newly diagnosed MCL is associated with high ORR and durable survival... - Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern eraAndrew M Evens
DO, MSc, Division of Hematology Oncology, 676 N St Clair S, Suite 850, Chicago, IL, 60611, USA
J Clin Oncol 28:1038-46. 2010..In addition, clinical factors at diagnosis identified patients with markedly divergent outcomes... - Follicular lymphoma: today's treatments and tomorrow's targetsVikas Aurora
Northwestern University Feinberg School of Medicine, Division of Hematology and Oncology, Department of Medicine and the Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Expert Opin Pharmacother 7:1273-90. 2006..Only well-designed clinical trials can provide answers to the many questions that remain regarding the optimal treatment and sequence of treatments for patients with follicular lymphoma... - CD23+ mantle cell lymphoma: a clinical pathologic entity associated with superior outcome compared with CD23- diseaseKatalin Kelemen
Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Am J Clin Pathol 130:166-77. 2008..In multivariate Cox regression analysis, CD23 status and leukemic-phase MCL were the most important factors predicting outcome... - Clinical, morphologic, immunophenotypic, and molecular cytogenetic assessment of CD4-/CD8-?? T-cell large granular lymphocytic leukemiaYi Hua Chen
Dept of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Am J Clin Pathol 136:289-99. 2011..Awareness of these features is important for early recognition and accurate diagnosis of patients with CD4-/CD8- ?? T-LGL leukemia... - G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysisAndrew M Evens
Division of Hematology Oncology, Lymphoma Program, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
Br J Haematol 137:545-52. 2007..0% and OS 91.3% (P = 0.46 and 0.67 respectively). Our experience suggests that ABVD may be safely and effectively administered at >99% dose-intensity without G-CSF support, regardless of the ANC... - Current controversies in follicular lymphomaVikas Aurora
Division of Hematology and Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine and the Robert H Lurie Comprehensive Cancer Center, 676 N St Clair Street, Suite 850, Chicago, IL 60611, USA
Blood Rev 20:179-200. 2006..Novel agents with varied mechanisms of action continue to be developed. Enrollment of patients into clinical trials designed to address the many unanswered questions in FL is essential to improving clinical outcomes... - Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomasJeffrey Cilley
Division of Hematology/Oncology, Department of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Haematologica 91:114-20. 2006..Whether this increase in radiation dose to the targeted lymphoma translates into more durable remissions and an improvement in overall survival requires further investigation... - Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin familyAndrew M Evens
Lymphoma Program, Division of Hematology Oncology, and Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Br J Haematol 141:676-80. 2008..g. 44% DLBCL vs. 11% of FL cases with moderate-to-high expression of HIF-1alpha and HIF-2alpha, P = 0.0017). These data demonstrate that HIF and the thioredoxin family are abnormally activated in lymphoma... - Radioimmunotherapy for the treatment of non-Hodgkin lymphoma: current status and future applicationsSairah Ahmed
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Leuk Lymphoma 51:1163-77. 2010..A reappraisal of prior data and examination of recently published and ongoing studies will be important in recognizing the potential benefit of RIT in the treatment of NHL... - Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphomaMarcie Tomblyn
Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Expert Rev Anticancer Ther 3:281-94. 2003..Based upon the current literature, hematopoietic stem cell transplant cannot be recommended as first-line therapy in patients with non-Hodgkin's lymphoma outside the setting of a clinical trial... - Lack of an association between Chlamydia psittaci and ocular adnexal lymphomaGrace S Zhang
Department of Ophthalmology, Northwestern University Chicago, IL 60611, USA
Leuk Lymphoma 48:577-83. 2007..psittaci infection in various geographic regions or technical differences in the application of the assays may underlie the variability in the association between C. psittaci and ocular adnexal lymphoma... - Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drugLarry Boehlke
Feinberg School of Medicine, Division of Hematology/Oncology, Department of Medicine and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 676 N. St. Clair St, Suite 850, Chicago, IL 60611, USA
Expert Opin Biol Ther 6:409-15. 2006..Its true value both as a single agent in heavily pretreated patients and in combination regimens will need to be established in Phase III trials... - Classical Hodgkin's lymphoma presenting with tongue involvement: a case report and review of the literatureDiana O Treaba
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
Clin Lymphoma Myeloma 6:410-3. 2006..Waldeyer's ring involvement by Hodgkin's lymphoma is uncommon with < 200 cases reported in the English literature and only 5 previous reports of Hodgkin's lymphoma involving the tongue... - Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantationPartow Kebriaei
Department of Medicine and Cancer Research Center, University of Chicago, 5841 S. Maryland Avenue, MC 2115, Chicago, IL 60637, USA
Leuk Res 28:537-40. 2004..The emergence of clonal hematopoiesis may provide insights into therapy-related leukemogenesis... - Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology GroupRalph M Meyer
Juravinski Cancer Centre and McMaster University, Hamilton, Ontario, Canada
J Clin Oncol 23:4634-42. 2005..We report results of a randomized trial comparing ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy alone with treatment that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma... - Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphomaDavid J Inwards
Mayo Clinic College of Medicine, Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, Minnesota 55905, USA
Best Pract Res Clin Haematol 19:669-84. 2006..Demonstration of improved disease control will ultimately require phase-III studies, though preliminary results are promising... - Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetanArturo Molina
Biogen Idec Inc, San Diego, CA 92122, USA
Curr Stem Cell Res Ther 2:239-48. 2007..Studies of (90)Y ibritumomab tiuxetan in the setting of allogeneic stem cell transplantation appear promising as well... - Hodgkin disease/lymphomaRichard T Hoppe
Stanford Comprehensive Cancer Center, USA
J Natl Compr Canc Netw 6:594-622. 2008 - Hodgkin disease/lymphoma. Clinical practice guidelines in oncologyRichard T Hoppe
J Natl Compr Canc Netw 4:210-30. 2006 - Bcl-B expression in human epithelial and nonepithelial malignanciesMaryla Krajewska
Burnham Institute for Medical Research, La Jolla, California 92037, USA
Clin Cancer Res 14:3011-21. 2008..Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported...